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Abstract Loss of cognitive function is one the most devas-
tating manifestations of ageing and vascular disease. Cogni-
tive decline is rapidly becoming an important cause of dis-
ability worldwide and contributes significantly to increased
mortality. There is growing evidence that hypertension is the
most important modifiable vascular risk factor for develop-
ment and progression of both cognitive decline and dementia.
High blood pressure contributes to cerebral small and large
vessel disease resulting in brain damage and dementia. A
decline in cerebrovascular reserve capacity and emerging
degenerative vascular wall changes underlie complete and
incomplete brain infarcts, haemorrhages and white matter
hyperintensities. This review discusses the complexity of
factors linking hypertension to brain functional and structural
changes, and to cognitive decline and dementia. The evidence
for possible clinical markers useful for prevention of de-
creased cognitive ability, as well as recent data on vascular
mechanism in the pathogenesis of cognitive decline, and the
role of antihypertensive therapies in long-term prevention of
late-life cognitive decline will be reviewed.
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Introduction
Arterial hypertension contributes to both the development and
progression of cerebrovascular disease [1]. There is growing
evidence that hypertension is the most powerful modifiable
risk factor for cerebral vessel dysfunction and might contrib-
ute to consequent cognitive decline [2, 3•]. The relationship
among ageing, hypertension and cognitive function is com-
plex and not completely understood. Nevertheless, blood
pressure might be considered a marker of cerebrovascular
health [4].
This review examines first, the epidemiology of dementia;
second, the evidence linking hypertension, ageing and cogni-
tive dysfunction; third, potential mechanisms underlying this
link; fourth, the benefits of antihypertensive treatment in
prevention of cognitive decline.
Epidemiology of Dementia
Increasing life expectancy observed worldwide results in a
growing prevalence of cognitive decline and dementia. In the
year 2000, the worldwide number of subjects with dementia
was estimated at about 25 million, corresponding to 6.1 % of
the population 65 years of age and older and to 0.5 % of the
worldwide population [5]. Almost 60 % of all demented
subjects were female. The worldwide annual cost of dementia
increased between 2005 and 2009 by 34% from 315 billion to
421 billion USD [6]. It is forecasted that the number of
demented elderly will increase to 63 million in 2030 and to
114 million in 2050 [5]. Because of the magnitude of the
problem dementia is clearly a burning medical, social and
economic burden.
Cognitive decline is a part of a natural history of brain
ageing. Cognitive decline may take different forms depending
on the severity of the process—from physiological cognitive
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ageing through mild cognitive impairment (MCI), a cognitive
decline greater than expected for an individual’s age and
education, however not affecting patients activities of daily
living, till dementia, a state in which cognitive impairment is
affecting activities of daily living. Many patients with MCI
have minor histopathological Alzheimer’s disease (AD)
changes, and more than half progress to full blown AD [7].
MCI patients can be divided into amnestic and non-amnestic
subtypes [8]. Amnestic MCI (30 % of MCI patients) likely
represents a prodromal form of AD, with about 12 %
converting to AD each year [9].
Impairment of memory, abstract thinking and judgment are
the hallmarks of dementia. Clinical assessment besides mem-
ory includes evaluation of language, attention, visuospatial
abilities and executive functions.
Dementia syndromes are divided into neurodegenerative
disease, vascular dementia (VaD) and mixed variants. AD,
being the most common neurodegenerative form, accounts for
approximately 65 % of all cases of dementia in the white
population [10]. Vascular dementia constitutes the second
most common type of dementia, accounting for 15 to 20 %
of all cases of dementia [11]. Of note, “vascular dementia” is a
concept rather than a nosological entity. It encompasses a
variety of conditions and dementia mechanisms including
ischaemic, ischaemic-hypoxic or haemorrhagic brain lesions
as a result of cerebrovascular disease and cardiovascular path-
ological changes [12].
Although the majority of dementias are primary neurode-
generative diseases of unknown cause, recent studies have
shown that cerebrovascular disease and microscopic vascular
lesions are frequently found in patients affected by those
conditions [13••, 14]. Moreover, cerebrovascular disease has
been shown to be associated with more severe cognitive
decline in AD, the most common cause of dementia [15, 16].
Blood Pressure and the Risk of Cognitive Decline
The relationship between blood pressure (BP) and cognition
has been examined across various neuropsychological do-
mains. This relationship is strongly influenced by age. Fur-
thermore, the moment of blood pressure assessment is of
critical importance, and one should discriminate cross-
sectional observations from long-term follow-up studies tak-
ing into account the role of BP levels in the years preceding
cognitive decline.
Cross-Sectional Studies
In younger patients, increased BP has been associated with
impaired cognition. A recent study by Shehab et al. assessed
the relationship between cognitive performance and white
coat hypertension and borderline hypertension in a cohort of
relatively young individuals (mean age ± SD, 38.2±
10.8 years). An analysis of clinic and 24-h ambulatory blood
pressure monitoring and cognitive performance parameters
showed lower cognitive function in patients with white coat
hypertension (memory) and borderline hypertension (slower
reaction time) compared with controls [17].
Mahoney et al. have recently shown that in individuals
aged >70, those with low systolic blood pressure (SBP) dem-
onstrate worse executive attention than individuals with nor-
mal to high SBP. Diastolic blood pressure (DBP) had no
significant effect in this study. The authors suggested that
the maintenance of optimal SBP levels in older adults might
be crucial for optimal cognitive functions that depend on the
frontal lobes [18].
In the group of very old individuals (Australian centenar-
ians, mean age 101 years), low SBP and narrower pulse
pressure were associated with poorer cognitive (measured by
MMSE score) and functional status (measured using the Katz
Index of Independence in Activities of Daily Living) [19]. The
same findings were found in a cohort of Polish patients [20].
Taken together, these findings indicate that normal blood
pressure is associated with the optimal cognitive performance
independent of age. In the elderly, a reversed cross-sectional
relationship between blood pressure and cognition might be
secondary to brain atrophy, neuronal death and disturbances in
cholinergic neurotransmission (see below) or reflect reversed
epidemiology resulting from high hypertension-related stroke
mortality in younger patients. Poor cognitive performance in
elderly with currently low BP is especially pronounced in
those with a history of hypertension. Thus, the relationship
between BP and dementia might be somehow similar to that
between hypertension and congestive heart failure. Hyperten-
sion might contribute to the development of both cognitive
decline and heart failure at earlier stages of the diseases. A
drop in blood pressure reflects failure of compensatory mech-
anisms, indicates a severe stage of the disease and is probably
associated with irreversibility of the process.
Long-Term Studies
Baseline high blood pressure inmiddle-aged subjects has been
linked to future cognitive decline, mild cognitive impairment
and dementia [21–24]. This association was especially evident
in studies focussing on VaD [25, 26]. Among different BP
components, SBP appears to be the strongest predictor of
cognitive decline in most of the studies.
The role of midlife BP in the development of cognitive
decline has been recently re-assessed in several important
publications. Elevated BPwas associated with faster cognitive
decline in patients diagnosed with MCI. Over a 2-year obser-
vation of 1,385 subjects diagnosed with MCI, elevated BP
(mainly SBP) was associated with impaired visuomotor se-
quencing, set shifting and naming [27].
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In the Hoorn Study, Reijmer et al. investigated the relation
between vascular risk factors and late-life cognitive perfor-
mance after 15 years of follow-up in a cohort of 380 non-
demented subjects (mean baseline age 58±6 years). Individ-
uals with poor information-processing speed had higher levels
of systolic blood pressure at baseline [mean difference (SE)
11.6 (2.6) mmHg, p <0.001], and the relationship gradually
attenuated with increasing age [28].
In the Honolulu Heart Program/Honolulu Asia Aging
Study, a 25-year observation of middle-aged subjects (mean
age, 54 years) indicated that 27 % of dementia cases could be
attributed to untreated mid-life levels of SBP >120 mmHg,
which translates into 17 excess cases per 1,000. The novel
finding of the study was that there were 17.7 % of cases that
were attributable to prehypertensive levels (SBP 120–<
140 mmHg) of BP [29•].
The relationship betweenmid-life BP and cognitive decline
has also been recently confirmed by the 40-year follow-up
study of a population-based cohort of the Uppsala Longitudi-
nal Study of Adult Men. Of 2,268 individuals initially en-
rolled in the study, 349 developed dementia. Systolic blood
pressure increased the risk of vascular and all-type dementia
[30•]. The risk was further potentiated by other cardiovascular
risk factors, which is consistent with the results of another
study demonstrating the impact of obesity-related metabolic
abnormalities on cognitive performance [31].
Importantly, hypertension usually coexists with lipid dis-
orders (even in >50 % of individuals over 55 years of age)
[32–34] Thus, the link between hypertension and cognitive
function can be affected by coexisting dyslipidaemia and its
treatment with statins, which might increase the risk of cog-
nitive impairments, especially in elderly patients (http://www.
fda.gov/drugs/drugsafety/ucm293101.htm). While the above-
mentioned evidence supporting the contribution of midlife
hypertension to cognitive decline is growing, the impact of
late-life BP is more controversial. The results of the earlier
studies evaluating the influence of late-life BP on cognition
were conflicting. Some of the investigators reported a signif-
icant effect of hypertension on cognitive decline [35, 36],
while the others found no effect [37, 38] or suggested a U-
shape relationship between BP and cognitive function [39,
40]. Several recent studies have revisited this issue.
Yasar et al. analysed the association of late-life (>70 years)
blood pressure on cognitive performance in a cohort of older,
non-demented participants in the Women’s Health and Aging
Study II. Cognitive abilities were assessed at baseline and
after 9-year follow-up. In a group aged 70-75 years, high PP
≥71 mmHg was associated with impaired verbal learning
while in the group aged 76-80 years, high SBP ≥160 mmHg
or PP ≥84 mmHg was associated with decreased executive
functions. These findings indicate that not only midlife but
also late-life BP may be associated with cognitive decline
[41].
In a group of Korean patients aged 40-95 years, hyperten-
sion increased the risk of VaD by more than two fold in both
men and women. This association was attenuated in patients
older than 65, but remained significant in men. This study
showed no interaction between hypertension and diabetes on
the risk of dementia [42].
In the Hisayama study 668 non-demented Japanese
patients aged 65-79 years were followed up for 17 years.
Within that time 76 subjects developed vascular demen-
tia. After adjusting for confounding factors, subjects
with prehypertension and stage 1 or stage 2 hyperten-
sion had 3.0-, 4.5- and 5.6-fold greater risk of vascular
dementia, respectively, compared with subjects with nor-
mal blood pressure [43].
The relationship between MCI and the risk of progression
to dementia was assessed by Oveisgharan and Hachinski.
Nine hundred ninety individuals with a mean age of 83 years,
diagnosed with MCI (affecting memory, executive functions
or both) were followed up for up to 5 years. The rate of
progression to dementia was highest in patients with
impaired executive functions (57.7 % having hyperten-
sion progressed to dementia compared with 28.0 %
having normotension, p =0.02) [44].
Interestingly, a BP decrease has been shown to precede a
clinical manifestation of dementia in the elderly and very
elderly subjects [45, 46]. As an explanation, neuronal death
and disturbances in cholinergic neurotransmission affecting
the autonomic centres in the brain have been suggested.
Furthermore, progressive physical inactivity associating cog-
nitive decline may be also a substantial factor leading to a fall
in blood pressure [47].
Alzheimer’s Disease
While the strong association between elevated blood
pressure and future development of VaD is well docu-
mented, the relationship between hypertension and AD
is less clear [25, 26, 45, 48–54].
The recently published Uppsala Longitudinal Study of
Adult Men, despite extended follow-up (up to 40 years), was
not able to find any relationship between middle-life BP and
the risk of AD [30•]. Similarly, other studies found no associ-
ation between elevated BP and AD [44, 55]. In fact, increased
DBP was significantly associated with the decreased develop-
ment of AD [55].
Mechanism Underlying the Link Between Hypertension
and Cognitive Decline
Cerebrovascular dysfunction plays the key role in cognitive
and behavioural impairment. With ageing profound alter-
ations in the structure, function and organisation of cerebral
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blood vessels occur. First, the number of cerebral capillaries in
the cortex is reduced, and their basement membranes become
thickened and fibrotic [56]. White matter vessels appear more
tortuous with ageing [57]. These alterations result in reduction
of resting cerebral blood flow (CBF), attenuation of cerebro-
vascular reserves and dysfunction of the mechanisms regulat-
ing the cerebral circulation [56–58]. These age-related alter-
ations might be potentiated by hypertension.
Hypertension-related cognitive decline is a consequence of
interplay between functional blood flow reorganisation and
brain vascular damage. Focal and regional dissociations in
blood flow and function lead to lesions affecting both grey
and white matter, manifesting as complete and incomplete
microinfarcts, haemorrhages and white matter hyperintensities
(WMHs).
Failure of the Cerebral Regulatory Function
Recent evidence has emerged showing that hypertension itself
has a direct negative effect on cerebral vasoreactivity that is
comparable to that observed in stroke [59•]. Consequently,
hypertension might increase the risk of microvascular brain
damage and impairment in mobility, cognition and mood [60].
Pressure autoregulation and CO2 reactivity are the two
clinically relevant biomarkers of vascular reserve [61]. Im-
pairment of the vascular reserve might mediate the link be-
tween BP and cognition. The neurovascular regulatory sys-
tems are widely involved in cognitive and motor functions. In
case of failure of the cerebral regulatory function, including
cholinergic neuronal processes, the brain might become more




Both human ageing and hypertension are associated with
brain atrophy [63•]. The structural changes that are noted in
patients with MCI involve mesial and lateral temporal regions
as well as cingulate, parietal and mid-frontal areas. The earli-
est changes however do occur within the hippocampus and
entorhinal cortex [64]. Regions emerging as especially vul-
nerable to advanced age and to essential hypertension include
the prefrontal cortex, hippocampus, inferior temporal cortex
[65, 66] and inferior parietal lobule [67]. Of note, also brain
regions that are only moderately vulnerable to ageing, e.g., the
supplementary motor areas [68], cuneus [69], thalamus [70]
and entorhinal cortex [67], are affected by hypertension. Thus,
high blood pressure may affect the grey matter structure not
only by potentiation of age-dependent changes, but also by
mechanisms that are hypertension-specific and independent of
ageing.
White Matter Changes
One of the most common manifestations of brain ageing is
reduction in white matter integrity [71], which radiologically
manifests as a leukoaraiosis – areas of decreased density on
CT scans or increased signal intensity on T2/FLAIR se-
quences on MRI scans [72]. White matter hyperintensities
are associated with future risk of stroke, cognitive decline,
dementia and death [73•]. Although the aetiology ofWMHs is
not clear, they are believed to be one of the manifestations of
cerebral small vessel disease [74, 75••].
The association between hypertension and WMHs is well
established [76, 77]. High blood pressure is related to cerebral
WMH progression [78•] and to increased risk of incident
infarcts [79]. Both baseline BP and its increase over a mean
of 7 years have been associated with greater WMH volume
[80]. A recent study evaluating WMH progression over a
relatively short period of time has shown that high blood
pressure or a history of hypertension was associated with
greater deep WMH volume in the frontal lobe [81], indicating
that the frontal lobe is especially susceptible to the
hypertension-related white matter degradation. Hypertension
may be associated not only with visible lesions, but also with
white matter microstructure alterations, suggesting an impor-
tant role of blood pressure in age-related cerebral tissue dam-
age [82].
Larger WMH volume in hypertensive individuals has been
linked to inflammatory factors, endothelial dysfunction and
poorly perfused watershed areas [83]. An increase in WMH
volume is lower in controlled treated hypertensives compared
with uncontrolled untreated hypertensives, despite the higher
baseline WML load [78•]. Thus, successful hypertension
management might reduce progression of WML.
There is accumulating evidence that the negative effect of
elevated blood pressure on lifelong cognitive ageing is prob-
ably mainly mediated by WMHs [84]. An increase of WMH
volume is associated with a decrease in episodic memory and
executive function. Interestingly, the evolution of existing
WMHs was more relevant than the formation of new ones
[85]. The presence of retinopathy, as another marker of small
vessel disease, has recently been shown to correspond to
cognitive impairment [86]. Additionally, cerebral microbleeds
(CMBs), another type of brain lesion related to the pathology
of small vessels, might also be associated with hypertension
and cognitive decline. However, the role of CMBs as predic-
tors of disease needs to be further elucidated [87].
Large Artery Dysfunction
Both cognitive decline and brain damage might be related to
impairment of large artery function. Pulse pressure (PP), a
marker of arterial stiffness, has been connected with the risk of
cognitive decline [88] and AD [89, 90], impaired Aβ removal
550 Curr Hypertens Rep (2013) 15:547–558
[91] and higher prevalence of WMHs [92]. Elevated pulse
pressure increases the risk of cognitive decline and impair-
ment in language abilities in non-demented older adults [93].
In another study in middle-aged healthy individuals, PP was
an independent predictor of both episodic memory perfor-
mance and speed of memory retrieval [94].
Nation et al. have recently assessed the relation between
late-life PP and the severity of post-mortem histopathological
indicators of cerebrovascular disease and cerebral amyloid
angiopathy in autopsy-confirmed AD patients. Higher PP
was associated with more severe cerebrovascular disease,
but not with the presence of cerebral amyloid angiopathy or
the severity of AD, indicating late-life PP is associated with
cerebrovascular disease rather than with AD itself [95].
Pulse pressure is an indirect marker of arterial stiffness, which
might bemuchmore precisely assessed bymeasurement of pulse
wave velocity (PWV). The analysis of the association between
PWV and cognitive function performed by Rabkin and Jarvie
indicates the inverse relationship between PWV and cognitive
performance. Moreover, PWV is higher in patients with VaD
compared with controls and AD patients [96•]. Those findings
are consistent with the results of a recent cross-sectional study by
Zhong et al., which has shown elevated carotid-femoral PWV
(>12 m/s) to be associated with worse cognitive function in the
elderly population (mean age 75 years) [97].
Renin-Angiotensin System
Recent research supports an important role of the renin-
angiotensin system in both brain ageing [98] and in dementia
progression [99]. The effects of angiotensin II on vascular and
metabolic homeostasis, amyloid metabolism, as well as on
learning and memory might explain this link. Angiotensin is
active in the nucleus tractus solitarius and the dorsolateral
ventral medulla-BP regulatory area [100]. Blood angiotensin
is also known to influence the neuroendocrine system and the
brain through the circumventricular organ [101].
Altered Metabolism
Cerebral metabolism is specifically altered in patients with
dementia, as indicated by FDG-PET studies [102]. Reduction
in the cerebral metabolic rate of glucose, an index of neural
metabolic activity and density [103], can precede the onset of
dementia by many years [104]. Finally, PET-amyloid tracers
can discriminate normal patients at higher versus lower risk
for AD, and the retention of amyloid tracer in a healthy person
is a risk factor for later cognitive decline [102, 105].
Genetic Factors
Several recent studies have assessed the association between
genetic risk factors of dementia (ApoE ε4), WMLs and
hypertension [29•, 106, 107]. Yasuno et al. have demonstrated
the synergistic effect of hypertension and the ApoE ε4 allele
on the acceleration of cognitive decline in elderly patients
[108]. Schuur et al. have shown that ApoE ε4 homozygotes
had more WML, lacunes and microbleeds than those without
the ε4 allele [109].
Psychosocial Stress
The term “hypertension” itself suggests a relationship with
some kind of “tension”, and high BP has been linked to
greater psychosocial stress [110, 111]. However, longitudinal
studies have revealed that the overall relationship between
psychological factors and hypertension is rather low [112•].
Nevertheless, normotensive subjects at risk for hypertension
have been reported to show altered neural responses to psy-
chological tasks, in terms of both involved brain networks and
neuropsychological performance [113]. This suggests influ-
ences of essential hypertension on the brain may be not always
secondary to peripheral BP [113].
Antihypertensive Therapy and Cognition
The influence of antihypertensive therapy on the risk of de-
mentia was assessed in several longitudinal studies. By June
2010 the results of six main randomised trials considering this
issue has been published. On the basis of those trials and five
meta-analyses, the American Heart Association/American
Stroke Association formed recommendations on the treatment
of hypertension in the prevention of dementia. AHA/ASA
experts suggest that (1) in patients with stroke lowering of
blood pressure is effective in reducing the risk of post-stroke
dementia (class I; level of evidence B), (2) there is reasonable
evidence that in middle-aged and young elderly subjects,
lowering blood pressure can be useful for the prevention of
late-life dementia (class IIa; level of evidence B) and (3) the
usefulness of lowering blood pressure in people >80 years of
age for the prevention of dementia is not well established
(class IIb; level of evidence B) [114••].
Since that time the results of the ONTARGET/
TRANSCEND study have been published [115•]. The
ONTARGET study was a double-blind, double-dummy,
randomised controlled trial evaluating the effects of standard
doses of an angiotensin-converting enzyme (ACE) inhibitor
(ramipril), an angiotensin-receptor blocker (telmisartan) and a
combination of the drugs on cardiovascular outcomes in 25,
620 participants. In the parallel TRANSCEND trial, the ef-
fects of telmisartan were compared with those of placebo in 5,
926 participants intolerant to ACE inhibitors. Secondary end-
points included cognitive impairment and cognitive decline.
Over a period of 56 months of follow-up in ONTARGET,
cognitive impairment occurred in 652 (8 %) of 7,865 patients
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treated with ramipril, 584 (7 %) of 7,797 treated with
telmisartan and 618 (8 %) of 7,807 treated with combination
treatment [combination vs. ramipril, odds ratio (OR) 0.95,
95 % CI 0.85-1.07, p =0.39; telmisartan vs. ramipril, OR
0.90, 0.80-1.01, p =0.06). In TRANSCEND, cognitive im-
pairment occurred in 239 (9 %) of 2,694 participants treated
with telmisartan compared with 245 (9 %) of 2,689 allocated
placebo (OR 0.97, 0.81-1.17, p =0.76). There were also no
differences in cognitive decline between the groups [115•].
In 2011 Staessen at al. performed a meta-analysis of eight
studies. The results showed that blood pressure lowering in all
trials combined did not reduce the risk of dementia. However,
the reduction was significant (−18 %) for trials involving a
diuretic or dihydropyridine calcium channel blocker as part of
active treatment. This was not the case in trials of renin system
inhibitors (+1 %). According to the authors this difference
between drug classes might be explained by the amount of
blood pressure reduction because in weighted metaregression
analysis lowering of systolic pressure explained 41 %
(p =0.08) of the risk reduction [116•].
Several smaller studies were published in recent years.
Influence of the angiotensin receptor blocker (ARB)
eprosartan on trends in cognitive performance was evaluated
in the Observational Study on Cognitive Function and SBP
Reduction (OSCAR). The main finding of the study published
in 2008 was that 6-month hypertensive therapy based on
eprosartan was associated with a significant reduction in mean
systolic BP (SBP) and a significant improvement in mean
Mini-Mental State Examination (MMSE) score (p <0.0001
for both outcomes) [117]. The recent analysis was focussed
on the influence of eprosartan on trends in cognitive perfor-
mance in the cohort of patients with difficult-to-treat hyper-
tension (DTTH) (not satisfactorily controlled despite the use
of at least 3 antihypertensive drugs). The reduction in BP in
the DTTH cohort during the 6-month observation period
coincided with a 1-point increase in average MMSE. The
mean improvement was similar as in one of the studies indi-
cating therapeutic benefit from cholinesterase inhibitors in
patients with Alzheimer’s disease [118].
Of interest are the results of a small Japanese study inves-
tigating the effect of telmisartan on cognition and regional
cerebral blood flow in hypertensive patients with AD. Com-
pared to amlodipine, treatment with telmisartan was not asso-
ciated with cognitive decline (measured by the ADAS-Jcog
test) after 6 months of treatment and, furthermore, improved
cerebral blood flow in several brain subregions [119].
A cohort of 599 subjects aged 85 years was enrolled into
the Leiden 85-plus Study. Cardiovascular risk factors (among
them SBP and DBP) and cognitive performance were
assessed annually during a 5-year follow-up. Themain finding
of the study was that late-life changes in global cognitive
function preceded changes in values of vascular risk factors
in subsequent years, whereas changes in values of midlife
vascular risk factors did not precede changes in global cogni-
tive function [120].
The relationship between blood pressure and WML vol-
ume progression was assessed in a study by Verhaaren et al. In
a cohort of 665 non-demented subjects, after adjustment for
age, sex and cardiovascular risk factors, both systolic and
diastolic blood pressures were significantly associated with
annual WML progression. After adjustment for baseline
WML volume, only SBP remained significantly associated.
An interesting finding of the study is that people with uncon-
trolled untreated hypertension had significantly more WML
progression than people with uncontrolled treated hypertension
[78•].
After the 6-year follow-up of elderly patients (aged ≥65
and ≤80 years) with a history of treated hypertension (patients
with the history of stroke, transient ischaemic attack, diabetes
mellitus, atrial fibrillation, cardiac surgery, dementia or de-
pression were excluded), cognitive impairment worsened in
the areas related to executive function. Memory did not
change [121].
The risk factors for the development of WML were
assessed by Vourinen et al. After an average follow-up of
21 years the risk of late-life (65-79 years) WML was associ-
ated with midlife hypertension. Both elevation of blood pres-
sure and decrease of blood pressure between midlife and late-
life were associated with an increased risk of WML develop-
ment even after adjustment for antihypertensive therapy [122].
Finally, a small study by Watfa et al. showed that calcium
channel blocker (CCB) use might be associated with better
memory performance independent of the blood pressure level.
The authors suggest that it may be associated with special
protective effects of CCB’s on cognition [123].
Taken together, the results of the studies evaluating
the impact of hypertension treatment on cognitive func-
tion are somewhat disappointing. Of note, these studies
focussed primarily on white matter changes. Cognitive
decline is more closely related to grey matter changes
than to white matter changes. Importantly, there is no
evidence that treatment of hypertension attenuates the
progression of grey matter changes [124•], at least in
short-term observations. Continued atrophy in the pres-
ence of successful BP reduction stimulates further stud-
ies testing the hypothesis that essential hypertension (1)
may directly affect the brain via factors that are not
mediated by increased BP and (2) from its onset may
be a disease of the brain as well as of the vasculature
[113]. Studies with longer intervention durations are
needed to determine whether successful hypertension
treatment would affect the grey matter changes. Recent-
ly, the ESH-ESC guidelines have also acknowledged
that evidence on antihypertensive therapy and cognition
is weak and have preferred not to make any recommen-
dations but to encourage new trials [125].
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Dementia Prevention Studies
The aetiology of dementia is multifactorial. It is estimated that
up to 50 % of the AD cases worldwide are attributable to
cardiovascular risk factors and physical and cognitive inactiv-
ity [126]. Among cardiovascular risk factors reported to pro-
mote progressive cognitive decline, reduced cardiac output,
atrial fibrillation, left ventricle hypertrophy in midlife as well
as coronary heart disease are reported as the leading condi-
tions of the “cardiogenic dementia” [127–130]. Aortic stiff-
ness is thought to be one of the most important extracardiac
vascular risk factors playing a crucial role in the initiation of
dementia [131]. Interestingly, the presence of the ApoE4
allele, a genetic risk factor for Alzheimer’s disease, increases
the risk of CAD by 40 % [132].
Vascular risk factors have been shown to be associated with
an increased risk of dementia and AD in several population-
based studies. Interestingly, for diabetes this relation is con-
sistent until late life [133], while for hypertension, hypercho-
lesterolemia and obesity the relationship is not linear and
disappears in late life [23, 134, 135]. Similarly, LVH loses
its predictive value for cognitive decline in old age [130].
To date the strongest effect towards the prevention of
dementia has been observed for antihypertensive treatment,
with a hazard ratio of 0.87 (95 % CI 0.76-1.00) [136]. How-
ever, the results of longitudinal studies examining the benefit
of antihypertensive treatment on cognitive function are not
conclusive [137, 138]. Among recent randomised controlled
trials examining the impact of antihypertensive therapy on
cognitive function, three studies (SYST-EUR, PROGRESS,
HOPE) found positive results, while the other four (MRC,
SHEP, SCOPE, HYVET-COG) trials reported no significant
effects [139]. Consequently, the role of antihypertensive ther-
apy in preventing cognitive disorders remains a matter of
debate, especially in elderly free of stroke subjects.
Newly founded in 2011, the European Dementia Preven-
tion Initiative (EDPI) is an important step in further dementia
research [140]. Four on-going large RCTs (preDIVA, FIN-
GER, MAPT, ESH-CHL-SHOT) will assess the role of car-
diovascular and lifestyle-related risk factor modification in
preventing or delaying dementia.
Conclusions
Hypertension contributes to both early cerebrovascular brain
ageing and cognitive decline. Subclinical brain damage in-
cluding WMLs links hypertension to increased risk of cogni-
tive impairment. Although the relationship between hyperten-
sion and dementia is well established, the impact of antihy-
pertensive treatment and management of other risk factors on
cognition is less clear. Peripheral BP is probably not an
optimal indicator of cerebrovascular health and risk.
It is feasible that more precise assessment of central
or regional (brain-specific) BP regulation will increase
our knowledge on both cerebrovascular disease and
hypertension-related dementia. Further studies based on
novel methods of cardiovascular phenotyping and brain
imaging are needed. This might improve cerebrovascular
risk assessment. One might envisage the introduction of
a scoring system evaluating global brain damage risk.
Such a NEUROSCORE system, somehow analogous to
the cardiovascular EUROSCORE, might result in better
prevention of cognitive decline.
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